Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine.

MLA

Webster, Rebecca, et al. “Safety, Infectivity and Immunogenicity of a Genetically Attenuated Blood-Stage Malaria Vaccine.” BMC Medicine, vol. 19, no. 1, Nov. 2021, p. 293. EBSCOhost, https://doi.org/10.1186/s12916-021-02150-x.

APA

Webster, R., Sekuloski, S., Odedra, A., Woolley, S., Jennings, H., Amante, F., Trenholme, K. R., Healer, J., Cowman, A. F., Eriksson, E. M., Sathe, P., Penington, J., Blanch, A. J., Dixon, M. W. A., Tilley, L., Duffy, M. F., Craig, A., Storm, J., Chan, J.-A., … McCarthy, J. S. (2021). Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine. BMC Medicine, 19(1), 293. https://doi.org/10.1186/s12916-021-02150-x

Chicago

Webster, Rebecca, Silvana Sekuloski, Anand Odedra, Stephen Woolley, Helen Jennings, Fiona Amante, Katharine R Trenholme, et al. 2021. “Safety, Infectivity and Immunogenicity of a Genetically Attenuated Blood-Stage Malaria Vaccine.” BMC Medicine 19 (1): 293. doi:10.1186/s12916-021-02150-x.